PlumX Metrics
Embed PlumX Metrics

Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR‑positive tumors

Oncology Reports, ISSN: 1791-2431, Vol: 52, Issue: 5
2024
  • 0
    Citations
  • 0
    Usage
  • 0
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Mentions
    1
    • News Mentions
      1
      • News
        1

Most Recent News

New Doxorubicin Therapy Data Have Been Reported by Investigators at University of Jinan (Engineered Extracellular Vesicles With Polypeptide for Targeted Delivery of Doxorubicin Against Egfr-positive Tumors)

2024 NOV 06 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Current study results on Drugs and Therapies - Doxorubicin

Article Description

Lack of effective tumor‑specific delivery systems remains an unmet clinical challenge for the employment of chemotherapy using cytotoxic drugs. Extracellular vesicles (EVs) have recently been investigated for their potential as an efficient drug‑delivery platform, due to their good biodis‑ tribution, biocompatibility and low immunogenicity. In the present study, the formulation of GE11 peptide‑modified EVs (GE11‑EVs) loaded with doxorubicin (Dox‑GE11‑EVs), was developed to target epidermal growth factor receptor (EGFR)‑positive tumor cells. The results obtained demon‑ strated that GE11‑EVs exhibited highly efficient targeting and drug delivery to EGFR‑positive tumor cells compared with non‑modified EVs. Furthermore, treatment with Dox‑GE11‑EVs led to a significantly inhibition of cell proliferation and increased apoptosis of EGFR‑positive tumor cells compared with Dox‑EVs and free Dox treatments. In addition, it was observed that treatment with either free Dox or Dox‑EVs exhibited a high level of cytotoxicity to normal cells, whereas treatment with Dox‑GE11‑EVs had only a limited effect on cell viability of normal cells. Taken together, the findings of the present study demonstrated that the engineered Dox‑GE11‑EVs can treat EGFR‑positive tumors more accu‑ rately and have higher safety than traditional tumor therapies.

Bibliographic Details

Yang, Yuqing; Wang, Fang; Li, Yuqin; Chen, Ruxi; Wang, Xiangyu; Chen, Jiahong; Lin, Xi; Zhang, Haipeng; Huang, Youwei; Wang, Rui

Spandidos Publications

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know